scholarly journals Effects of Funding Policy Changes and Health Warnings on the Use of Erythropoiesis-Stimulating Agents

2012 ◽  
Vol 8 (3) ◽  
pp. 179-183 ◽  
Author(s):  
Matthew A. Weir ◽  
Tara Gomes ◽  
Eric Winquist ◽  
David N. Juurlink ◽  
Meaghan S. Cuerden ◽  
...  
Keyword(s):  
Effective Means ◽  
Funding Policy ◽  
Health Warnings ◽  
Policy Changes ◽  
Erythropoiesis Stimulating Agents ◽  
Patients With Cancer

Formulary access and safety warnings had significant impacts on the new use of ESAs in patients with cancer, suggesting that both are effective means of influencing the use of these drugs.

scholarly journals Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia

2017 ◽  
Vol 13 (6) ◽  
pp. e562-e573 ◽  
Author(s):  
Virginia Noxon ◽  
Kevin B. Knopf ◽  
LeAnn B. Norris ◽  
Brian Chen ◽  
Y. Tony Yang ◽  
...  
Keyword(s):  
South Carolina ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Advisory Committees ◽  
Criminal Conviction ◽  
Erythropoiesis Stimulating Agents ◽  
Off Label ◽  
Patient Costs ◽  
Patients With Cancer ◽  
The Us

Purpose: The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and weekly, respectively, although off-label, less frequent scheduling was common. In 2004, 2007, and 2008, a US Food and Drug Administration Advisory Committees warned of risks associated with erythropoiesis-stimulating agents. During this period, lawsuits alleging illegal darbepoetin marketing practices have concluded, resulting in $1.1 billion in fines and settlements and one criminal conviction. No prior study, to our knowledge, has reported on the use of darbepoetin versus epoetin for CIA. Methods: We evaluated the dosing, utilization, and costs of erythropoiesis-stimulating agents among 3,761 South Carolina Medicaid patients with CIA. Results: Epoetin and darbepoetin utilization rates were 22% and 28% in 2003, 10% and 33% in 2007, and 3% and 7% in 2010, respectively. Mean per-patient per-administration epoetin and darbepoetin doses were 40,983 IU and 191 µg, respectively, in 2003 and 47,753 IU and 369 µg, respectively, in 2010. Mean monthly patient costs for epoetin and darbepoetin were $1,030 and $981, respectively, in 2003 and $932 and $1,352, respectively, in 2010. Epoetin use decreased steadily between 2002 and 2010; darbepoetin use increased steadily between 2003 and 2007 and then decreased steadily thereafter. Per-patient dosing of darbepoetin, but not epoetin, increased steadily between 2003 and 2010, and monthly per-patient epoetin costs decreased 3% while the per-patients costs of darbepoetin increased 30% between 2003 and 2010. Conclusion: To our knowledge, our findings are the first data reporting on epoetin versus darbepoetin use for CIA and support recently concluded lawsuits involving allegations of illegal marketing practices of the manufacturer of darbepoetin.

scholarly journals Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer

2014 ◽  
Vol 86 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Azzour D. Hazzan ◽  
Hitesh H. Shah ◽  
Susana Hong ◽  
Vipulbhai Sakhiya ◽  
Rimda Wanchoo ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Erythropoiesis Stimulating Agents ◽  
Patients With Cancer

scholarly journals Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer

2009 ◽  
Vol 22 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Charles L. Bennett ◽  
Pamela S. Becker ◽  
Eric H. Kraut ◽  
Athena T. Samaras ◽  
Dennis P. West
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Erythropoiesis Stimulating Agents ◽  
Patients With Cancer

Use and cost of erythropoiesis-stimulating agents in patients with cancer

2009 ◽  
Vol 25 (7) ◽  
pp. 1775-1784 ◽  
Author(s):  
Gregory Daniel ◽  
Dana Hurley ◽  
Joanna L. Whyte ◽  
Vincent Willey ◽  
Marcus Wilson ◽  
...  
Keyword(s):  
Erythropoiesis Stimulating Agents ◽  
Patients With Cancer

It's Never a Five-Day Shoot: Queensland Screen Funding Policy and the Local Animation Industry

1999 ◽  
Vol 93 (1) ◽  
pp. 131-143
Author(s):  
Rebecca Farley
Keyword(s):  
Cultural Industries ◽  
Funding Policy ◽  
Policy Changes ◽  
Industrial Practice ◽  
Animation Industry ◽  
The Arts

A number of structural and policy changes have swept through Queensland's film funding organisations since 1996. Nonetheless, a monocular, rose-tinted view of what constitutes ‘industry’ has remained. Animation is one of many areas which are under-served, if not actively restricted, by this romantic view of industry. This paper looks at the capacity of Queensland's film funding bodies to fulfil the Arts Office's slogan: ‘to ensure success for Queensland's cultural industries’, both in their previous (1997) incarnation and since the implementation of the Weekes Report recommendations in 1998. It then engages with the aspects of industrial practice which are hampered by these gaps in policy.

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

The Lancet ◽  
2009 ◽  
Vol 373 (9674) ◽  
pp. 1532-1542 ◽  
Author(s):  
Julia Bohlius ◽  
Kurt Schmidlin ◽  
Corinne Brillant ◽  
Guido Schwarzer ◽  
Sven Trelle ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Randomised Trials ◽  
Erythropoiesis Stimulating Agents ◽  
Patients With Cancer
Sign in / Sign up

Export Citation Format

Share Document